Candid Therapeutics Acquired by UCB | Healthcare M&A Deal

UCB has acquired Candid Therapeutics, a medical devices business in California, for up to $2.2B. UCB acquisitions are aimed at expanding T-cell engager (TCE) antibody capabilities in immunology by adding Candid’s bispecific and trispecific antibody pipeline. Candid Therapeutics, based in San Diego, develops autoimmune and inflammatory disease candidates, including cizutamig, a BCMA x CD3 bispecific antibody for autoantibody-driven conditions. The strategic acquisition is structured as a platform acquisition and is expected to close after announced healthcare M&A steps, with deal value reported up to $2.2 billion.